BIT 2.86% 3.4¢ biotron limited

Ann: Letter to Shareholders, page-91

  1. 11,843 Posts.
    lightbulb Created with Sketch. 6001
    Always in the vacuum of News/ Updates there are questions surrounding "what are management up to , what are they achieving"?

    SH need to focus on the Game and not the players ... just because there is no market action doesn't mean that Management are inactive..
    Had a little more time to reflect on the last presentation , The CEO obviously has ignored previous correspondence from certain SH? in this game you have to "Craft" your questions so a CEO has the ability to answer...
    The recent message is " We have signed hundreds of NDA's" "we can not disclose who we are in Discussions with"
    Plus the big one I believe the market missed " We have Met our Primary Endpoints"

    BIT225-011 Phase 2 HIV Exploratory Efficacy Trial Meets Primary Objectives

     Preliminary analyses indicate that the primary objectives of the trial have been met.
     The results extend the previously reported effects of BIT225 to an HIV-infected population that has
    not achieved full immune reconstitution despite long-term suppressive antiretroviral treatment.

    The Directors of Biotron Limited (the Company) are pleased to advise that preliminary analyses of data from
    the BIT225-011 Phase 2 clinical trial of the Company’s lead antiviral drug BIT225 indicate that the primary
    objectives of the trial have been met.

    This longitudinal, open-label Phase 2 trial was designed to characterise the effect of BIT225 (200 mg, once
    daily) added to ongoing, suppressive standard of care antiretroviral therapy (cART) for twelve weeks in twenty
    HIV-1 infected, treatment-experienced participants who had achieved only partial immune reconstitution. Trial
    details are set out in the attached Addendum.
    The primary objectives of the trial were to evaluate the safety and tolerability of BIT225 in this patient
    population, as well as to determine the impact of the addition of BIT225 to cART on immune activation,
    inflammation and viral markers.

    Understand many are jaded with the Company and management but do keep in mind "All those that hold are Invested n the Same Company"
    Varying Views and Opinions are always welcomed on the Forums but just openly abusing and slagging other Posters does nothing to assist with welcoming potential new investors.. NZT
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
3.4¢
Change
-0.001(2.86%)
Mkt cap ! $30.67M
Open High Low Value Volume
3.5¢ 3.5¢ 3.4¢ $16.72K 479.1K

Buyers (Bids)

No. Vol. Price($)
1 88413 3.4¢
 

Sellers (Offers)

Price($) Vol. No.
3.5¢ 73009 3
View Market Depth
Last trade - 15.48pm 16/07/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.